MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Harmony Biosciences Holdings Total Assets 2011-2026 | HRMY
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Harmony Biosciences Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 999 M | 811 M | 674 M | 433 M | 427 M | 107 M | 89.3 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 999 M | 89.3 M | 506 M |
Quarterly Total Assets Harmony Biosciences Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.21 B | 1.11 B | 1.06 B | 999 M | 928 M | 858 M | 847 M | 811 M | 778 M | 760 M | 715 M | 674 M | 643 M | - | 464 M | 433 M | 391 M | 360 M | 337 M | 427 M | 427 M | 427 M | 427 M | 107 M | 107 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.21 B | 107 M | 637 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
89.3 M | $ 1.9 | -3.11 % | $ 107 M |  China |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K |  USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.31 | -4.06 % | $ 7.96 B |  Australia |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.58 B | $ 25.87 | -0.79 % | $ 1.25 B | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
10.1 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
58.8 M | - | - | $ 269 M | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
1.18 B | $ 215.29 | 4.59 % | $ 5 B |  Danmark |
 |
BioNTech SE
BNTX
|
22.5 B | $ 105.97 | -2.78 % | $ 27.2 B | Germany |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.71 | 1.88 % | $ 17 M | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
1.39 B | $ 64.74 | 1.41 % | $ 8.66 B | USA |
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 3.96 | -1.0 % | $ 8.62 B |  Israel |
 |
BeiGene, Ltd.
BGNE
|
5.92 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 9.63 | -0.93 % | $ 1.56 B | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
283 M | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
23.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioLineRx Ltd.
BLRX
|
38.9 M | $ 2.97 | 3.12 % | $ 908 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
28 B | $ 164.87 | 0.27 % | $ 24 B | USA |
 |
Bio-Path Holdings
BPTH
|
3.22 M | - | - | $ 100 K | USA |
 |
BioVie
BIVI
|
21.6 M | $ 1.23 | 2.07 % | $ 1.82 M | USA |
 |
Baudax Bio
BXRX
|
10 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Cara Therapeutics
CARA
|
126 M | - | -3.03 % | $ 260 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |